DOI: 10.36347/sjams.2016.v04i06.017

Pages: 1953-1955

Venous thromboembolism(VTE)is a frequent complication of cancer and cancer treatment and is associated with multiple clinical consequences including recurrent venous thromboembolism(VTE),bleeding,and increase in the risk of death.Low molecular weight heparins(LMWH) are often used for long term prophylaxis because of reduced need of coagulation monitoring, few major bleeding episodes and once daily dosing .Low molecular weight heparin have ability to reduce the incidence of VTE and prevent recurrent VTEvents in cancer patients.Malignant conditions are frequently associated with a hypercoagulable state,with recurrent thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the coagulation cascade. Heparin and, its pharmacokinetically improved versions, low molecular weight heparins are effective in the prevention and treatment of thromboembolic events in cancer patients.This review article explains the role of the thromboprophylaxis in cancer patients.